提案スペルによる検索:
"sdo opens" » "do open" (検索語の拡大), "fda opens" (検索語の拡大), "o opens" (検索語の拡大), "sddo opens" (検索語の拡大), "sdao opens" (検索語の拡大), "sdo openss" (検索語の拡大)
"eso open" » "so open" (検索語の拡大), "caso open" (検索語の拡大), "two open" (検索語の拡大), "esdo open" (検索語の拡大), "esao open" (検索語の拡大), "eso opens" (検索語の拡大)
"esmo open" » "esmdo open" (検索語の拡大), "esmao open" (検索語の拡大), "esmo opens" (検索語の拡大), "esto open" (検索語の拡大), "ecmo open" (検索語の拡大)
"o open" » "do open" (検索語の拡大), "ao open" (検索語の拡大), "o opens" (検索語の拡大)
検索結果 1 - 20 結果 / 957 検索語 '(((("eso open") OR ("esmo open"))) OR ((("sdo opens") OR ("o open"))))', 処理時間: 1.47秒 結果の絞り込み
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
A lei geral de proteção de dados e o open finance

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
Simulação de grandes escalas de uma chama turbulenta e radiante de metano usando o OpenFOAM

検索ツール: RSSフィード — 検索結果をメール — 検索の保存